BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 2420162)

  • 1. Cyclic nucleotide phosphodiesterase inhibition by a benzoic acid derivative.
    Killackey JJ; Killackey BA; Philp RB
    Agents Actions; 1985 Dec; 17(2):192-6. PubMed ID: 2420162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from the cytosol of human platelets.
    Grant PG; Mannarino AF; Colman RW
    Thromb Res; 1990 Jul; 59(1):105-19. PubMed ID: 2169075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do conventional plasma cyclic nucleotide phosphodiesterase inhibitors really work in all situations?
    Wood PJ; Pao G; Ross G; Smith C
    Clin Chim Acta; 1981 Sep; 115(3):405-8. PubMed ID: 6271425
    [No Abstract]   [Full Text] [Related]  

  • 4. Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form.
    Lavan BE; Lakey T; Houslay MD
    Biochem Pharmacol; 1989 Nov; 38(22):4123-36. PubMed ID: 2480793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta.
    Lugnier C; Schoeffter P; Le Bec A; Strouthou E; Stoclet JC
    Biochem Pharmacol; 1986 May; 35(10):1743-51. PubMed ID: 2423089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of human lung cyclic GMP and cyclic AMP phosphodiesterases by certain nucleosides, nucleotides, and pharmacological phosphodiesterase inhibitors.
    Glass WF; Moore JB
    Biochem Pharmacol; 1979 Apr; 28(7):1107-12. PubMed ID: 87197
    [No Abstract]   [Full Text] [Related]  

  • 7. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation.
    Hidaka H; Hayashi H; Kohri H; Kimura Y; Hosokawa T; Igawa T; Saitoh Y
    J Pharmacol Exp Ther; 1979 Oct; 211(1):26-30. PubMed ID: 226672
    [No Abstract]   [Full Text] [Related]  

  • 8. Cyclic nucleotide phosphodiesterase activity and the platelet release reaction.
    Taylor PM; Heptinstall S
    Thromb Haemost; 1978 Apr; 39(2):550-1. PubMed ID: 27878
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of diamide on cyclic AMP levels and cyclic nucleotide phosphodiesterase in human peripheral blood lymphocytes.
    Wedner HJ
    Biochim Biophys Acta; 1980 Apr; 628(4):407-18. PubMed ID: 6245710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of cyclic AMP and cyclic GMP phosphodiesterases of cardiac nuclear fraction.
    Ahluwalia GS; Rhoads AR
    Biochem Pharmacol; 1982 Mar; 31(5):665-9. PubMed ID: 6177320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic nucleotide phosphodiesterase activities of the embryonic chick ovary.
    Teng CT; Buchler B; Teng CS
    Gen Comp Endocrinol; 1981 Aug; 44(4):409-17. PubMed ID: 6167486
    [No Abstract]   [Full Text] [Related]  

  • 12. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells.
    Souness JE; Diocee BK; Martin W; Moodie SA
    Biochem J; 1990 Feb; 266(1):127-32. PubMed ID: 2155604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The isoenzyme selectivity of AH 21-132 as an inhibitor of cyclic nucleotide phosphodiesterase activity.
    Elliott KR; Berry JL; Bate AJ; Foster RW; Small RC
    J Enzyme Inhib; 1991; 4(3):245-51. PubMed ID: 1645399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum cyclic 3',5'-nucleotide phosphodiesterase in patients with various thyroid disorders.
    Nagasaka A; Hasegawa H; Hayami S; Hidaka H; Tanaka T; Niinomi M; Nihei N; Nakagawa H; Ohyama T; Aono T
    Enzyme; 1985; 33(1):18-24. PubMed ID: 2985379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High activity of cyclic 3',5'-nucleotide phosphodiesterase in sera of patient with phaeochromocytoma.
    Nakai A; Nagasaka A; Ohyama T; Aono T; Iwase K; Hasegawa H; Hayami S; Hidaka H; Tanaka T; Niinomi M
    Clin Endocrinol (Oxf); 1986 Apr; 24(4):409-14. PubMed ID: 3017609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylxanthine inhibitors of phosphodiesterases.
    Wells JN; Miller JR
    Methods Enzymol; 1988; 159():489-96. PubMed ID: 2457788
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea-pig peritoneal macrophages.
    Turner NC; Wood LJ; Burns FM; Gueremy T; Souness JE
    Br J Pharmacol; 1993 Apr; 108(4):876-83. PubMed ID: 8387385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic nucleotide phosphodiesterases from frog atrial fibers: isolation and drug sensitivities.
    Lugnier C; Gauthier C; Le Bec A; Soustre H
    Am J Physiol; 1992 Mar; 262(3 Pt 2):H654-60. PubMed ID: 1373036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydro- and tetrahydroisoquinolines as inhibitors of cyclic nucleotide phosphodiesterases from dog heart. Structure-activity relationships.
    Van Inwegen RG; Salaman P; St Georgiev V; Weinryb I
    Biochem Pharmacol; 1979 Apr; 28(8):1307-12. PubMed ID: 87199
    [No Abstract]   [Full Text] [Related]  

  • 20. Y-590 (a new pyridazinone derivative), a potent anti-thrombotic agent--II. Inhibition of platelet phosphodiesterase.
    Mikashima H; Nakao T; Goto K; Ochi H; Yasuda H; Tsumagari T
    Thromb Res; 1984 Sep; 35(5):589-94. PubMed ID: 6091293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.